Study of a long-acting inhaler for COPD symptoms and lung function
Part of Lungs & breathing clinical trials.
This trial tests a once-daily inhaler that combines a long-acting bronchodilator with a corticosteroid to see if it improves breathing, lung function, and quality of life in people with moderate-to-severe COPD who have significant shortness of breath.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 75 years old.
- You have a confirmed diagnosis of COPD with moderate-to-severe airflow limitation (FEV1 between 30% and 70% of normal).
- You have smoked for 10 pack-years or more (e.g., 1 pack a day for 10 years).
- You are limited by breathlessness during daily activities (score of 2 or higher on the mMRC scale).
- You do not have asthma or a history of asthma, and have not had a COPD flare-up or respiratory infection in the last 6 weeks (2 months if hospitalized).
- You have no serious heart conditions, other lung diseases, or other health issues that would make the study unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether using one or more inhalers, together with a smartphone app, can help people manage chronic obstructive pulmonary disease (COPD) better. You may be eligible if you have COPD, need “triple therapy” (three medicine types), and can use the app and surveys.
This trial tests a new inhaled medication, HRS-9821, in healthy people and in people with COPD. For COPD patients, the goal is to see how safe and well-tolerated multiple doses are, which could lead to a new treatment option.
This study tests whether a new approach can help relieve severe shortness of breath in people with COPD who are already on standard inhaler therapy. It may help you breathe easier and improve your daily life.
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
This study tests a new inhaled powder medicine (TQC3927) against an existing combination inhaler for treating COPD, a lung disease that makes breathing difficult. The goal is to see if the new medicine works as well or better and is safe for people with COPD.
This study tests a medication called Breztri aerosphere (a triple-combination inhaler) to see how safe and well-tolerated it is in Indian patients with COPD who have had recent flare-ups. It may help people who need better control of their breathing symptoms.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.